Mei-Ting Wang

Title: Innovations of Mei-Ting Wang in Drug Bioavailability

Introduction

Mei-Ting Wang is a notable inventor based in Taipei, Taiwan. He has made significant contributions to the field of pharmacology, particularly in enhancing drug bioavailability and clearance rates of analgesic agents. His innovative work has implications for improving therapeutic outcomes in pain management.

Latest Patents

Mei-Ting Wang holds a patent for "Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2B (UGT2B)." This patent describes a UGT2B inhibitor that can increase the bioavailability of drugs. The compound can be in a free base or a pharmaceutically acceptable salt form, selected from a diverse group of substances including capillarisin, isorhamnetin, and hesperetin, among others. Additionally, the patent includes a UGT2B enhancer that can enhance the clearance rate of morphine-like analgesic agents, featuring compounds such as nordihydroguaiaretic acid, quercetin, and luteolin.

Career Highlights

Mei-Ting Wang is affiliated with the National Defense Medical Center, where he conducts research aimed at advancing medical treatments. His work focuses on the development of compounds that can significantly impact drug metabolism and efficacy.

Collaborations

Mei-Ting Wang collaborates with esteemed colleagues, including Yoa-Pu Hu Oliver and Li-Heng Pao, who contribute to his research endeavors. Their combined expertise enhances the potential for innovative breakthroughs in their field.

Conclusion

Mei-Ting Wang's contributions to pharmacology through his patent on UGT2B inhibitors and enhancers demonstrate his commitment to improving drug therapies. His work is poised to make a lasting impact on the medical community and patient care.